Glenmark gets FDA nod for OTC eye solution

Glenmark Pharmaceuticals announced it has received final approval from the U.S. Food & Drug Administration (FDA) for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC). The FDA has determined the solution to be bioequivalent to Alcon Laboratories' Pataday Once Daily Relief Ophthalmic Solution. Glenmark Therapeutics Inc., USA, will handle distribution in the U.S. As of February 22, 2025, the Pataday market has annual sales of approximately $50.7 million, according to Nielsen data. Glenmark leadership stated the approval highlights its commitment to providing affordable over-the-counter solutions. The company's stock code on the Bombay Stock Exchange (BSE) is 532296.